Natixis Advisors LLC Lowers Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Natixis Advisors LLC trimmed its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 31.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,537 shares of the company’s stock after selling 7,160 shares during the quarter. Natixis Advisors LLC’s holdings in Vaxcyte were worth $1,272,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Whipplewood Advisors LLC acquired a new position in Vaxcyte during the 4th quarter worth about $28,000. Smartleaf Asset Management LLC boosted its stake in shares of Vaxcyte by 188.4% in the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares during the period. Blue Trust Inc. grew its holdings in shares of Vaxcyte by 100.0% in the fourth quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after purchasing an additional 371 shares in the last quarter. Assetmark Inc. increased its stake in Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after buying an additional 775 shares during the period. Finally, Nomura Asset Management Co. Ltd. acquired a new stake in Vaxcyte during the 3rd quarter worth approximately $92,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Andrew Guggenhime sold 8,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the transaction, the chief financial officer now owns 109,491 shares of the company’s stock, valued at $9,472,066.41. This trade represents a 6.81 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now directly owns 7,175 shares of the company’s stock, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,250 shares of company stock valued at $3,840,018. Insiders own 3.10% of the company’s stock.

Vaxcyte Stock Down 2.6 %

Shares of Vaxcyte stock opened at $71.90 on Wednesday. Vaxcyte, Inc. has a 52 week low of $58.10 and a 52 week high of $121.06. The firm has a market capitalization of $9.26 billion, a P/E ratio of -15.63 and a beta of 1.02. The firm’s 50 day moving average is $81.14 and its two-hundred day moving average is $93.33.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PCVX has been the topic of a number of recent research reports. Guggenheim reaffirmed a “buy” rating and set a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th. Needham & Company LLC restated a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group assumed coverage on Vaxcyte in a research report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.